Synchron is developing the Stentrode, the world's only endovascular BCI requiring no open brain surgery. Founded in Australia by neurosurgeon Tom Oxley, Synchron received FDA Breakthrough Device Designation in 2020 and initiated the SWITCH US pivotal trial in 2022. The company's key clinical and commercial differentiator is the minimally invasive procedure — implanted via catheter in about two hours — which dramatically expands the eligible patient population relative to open-brain competitors. Synchron has completed implants in over 10 patients across Australia and the United States.